Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting
Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting
复制标题
DOI：
10.1186/s40164-023-00404-3
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Bing Xu
中科院分区：
文献类型：
--
作者：
Zhijuan Lin;Long Liu;Zhifeng Li;Bing Xu
AbstractRecent evidence suggests that bispecific antibodies (BsAbs) exhibit promising efficacy and low toxicity even in heavily treated non-Hodgkin B-cell lymphoma (B-NHL). However, the role of BsAbs in previously untreated NHL and the efficacy and safety of BsAbs used in combination remain uncertain. We summarized data published at the 64th American Society of Hematology (ASH) Annual Meeting on BsAb monotherapy or combination therapy for first-line or relapsed/refractory B-NHL. BsAb monotherapy in elderly/unfit newly diagnosed (ND) DLBCL patients achieved ORR and CR rates of 56% and 43%, respectively. In addition, BsAbs combined with chemotherapy or other novel agents raised the ORR higher than 50% without increasing the incidence of grade ≥ 3 CRS. We conclude that BsAb monotherapy or combination therapy for first-line or relapsed/refractory B-NHL has high efficacy and satisfactory safety.
